These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36559062)

  • 1. Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution.
    Jara MO; Warnken ZN; Sahakijpijarn S; Thakkar R; Kulkarni VR; Christensen DJ; Koleng JJ; Williams RO
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amorphous Solid Dispersions and the Contribution of Nanoparticles to In Vitro Dissolution and In Vivo Testing: Niclosamide as a Case Study.
    Jara MO; Warnken ZN; Williams RO
    Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33466598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†.
    Hanada M; Jermain SV; Thompson SA; Furuta H; Fukuda M; Williams RO
    Mol Pharm; 2021 Jan; 18(1):198-213. PubMed ID: 33291881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions.
    Lang B; Liu S; McGinity JW; Williams RO
    Drug Dev Ind Pharm; 2016; 42(3):429-45. PubMed ID: 26355819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies.
    Chiang CW; Lubach JW; Chen T; Chin S; Ly J; Zhang W; Hou HH; Nagapudi K
    Mol Pharm; 2023 May; 20(5):2452-2464. PubMed ID: 37010134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
    Mudie DM; Stewart AM; Biswas N; Brodeur TJ; Shepard KB; Smith A; Morgen MM; Baumann JM; Vodak DT
    Mol Pharm; 2020 Dec; 17(12):4463-4472. PubMed ID: 32835489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
    Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
    Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of co-administered stabilizers on the biopharmaceutical performance of regorafenib amorphous solid dispersions.
    Müller M; Wiedey R; Hoheisel W; Serno P; Breitkreutz J
    Eur J Pharm Biopharm; 2021 Dec; 169():189-199. PubMed ID: 34756974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
    Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
    Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of diluents on the compaction, dissolution, and physical stability of amorphous solid dispersion tablets.
    Yu D; Hoag SW
    Int J Pharm; 2024 Apr; 654():123924. PubMed ID: 38395318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
    Salmani JM; Lv H; Asghar S; Zhou J
    Pharm Dev Technol; 2015 Jun; 20(4):465-72. PubMed ID: 24490758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular interactions of niclosamide with hydroxyethyl cellulose in binary and ternary amorphous solid dispersions for synergistic enhancement of water solubility and oral pharmacokinetics in rats.
    Bhanushali JS; Dhiman S; Nandi U; Bharate SS
    Int J Pharm; 2022 Oct; 626():122144. PubMed ID: 36029996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK modeling coupled with biorelevant dissolution to forecast the oral performance of amorphous solid dispersion formulations.
    Kambayashi A; Kiyota T; Fujiwara M; Dressman JB
    Eur J Pharm Sci; 2019 Jul; 135():83-90. PubMed ID: 31125680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
    Liu C; Liu Z; Chen Y; Chen Z; Chen H; Pui Y; Qian F
    Eur J Pharm Biopharm; 2018 Mar; 124():73-81. PubMed ID: 29305142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laser diffraction as a powerful tool for amorphous solid dispersion screening and dissolution understanding.
    Paisana MC; Lino PR; Nunes PD; Pinto JF; Henriques J; Paiva AM
    Eur J Pharm Sci; 2021 Aug; 163():105853. PubMed ID: 33865976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion.
    Song S; Wang C; Wang S; Siegel RA; Sun CC
    Int J Pharm; 2021 Dec; 610():121216. PubMed ID: 34688849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.